Hypersensitivity to quinine. Discontinue treatment if abnormalities develop; red rash, blister &/or cold-like symptoms; fever, rash, blister, peeling of skin & soft tissue eg, in mouth cavity, throat, nose, genitalia & conjunctivitis occur. Immediately discontinue treatment if patient develops pigmentary abnormality, visual field defect, or any other abnormality not explainable by difficulty in accommodation or presence of corneal opacities. W/draw therapy if weakness occurs. Anaemia, aplastic anaemia, agranulocytosis, decrease in WBC & thrombocytopenia. Increased risk of retinopathy. Severe hypoglycaemia including loss of consciousness. CNS damage including ototoxicity (auditory & vestibular toxicity, congenital deafness), retinal hemorrhages & abnormal retinal pigmentation. Patients taking medicines causing adverse ocular or skin reactions; w/ severe GI, neurological or blood disorders; G6PD, porphyria cutanea tarda; psoriasis. Perform periodic blood counts. Periodic exam of skeletal muscle function & tendon reflexes in all patients on long-term therapy. Consider ophthalmological exam (eg, testing visual acuity, careful ophthalmoscopy, fundoscopy, central visual field testing w/ red target, colour vision) before initiating treatment & repeat at least every 12 mth. Check blood glucose level. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Hepatic or renal disease. Not to be used during pregnancy. Lactation. Not to be used in childn w/ ideal body wt of <31 kg.
Sign Out
Continue with Google
Sign Up With Email
Already a member?
Sign In
